The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
Open accessAbstract
Objective: There is a clear need to develop biomarkers for Parkinson disease (PD) diagnosis, differential diagnosis of Parkinsonian disorders, and monitoring disease progression. We and others have demonstrated that a decrease in DJ‐1 and/or α‐synuclein in the cerebrospinal fluid (CSF) is a potential index for Parkinson disease diagnosis, but not for PD severity. Methods: Using highly sensitive and quantitative Luminex assays, we measured total tau, phosphorylated tau, amyloid beta peptide 1–42 (Aβ 1–42), Flt3 ligand, and fractalkine levels in CSF in a large cohort of PD patients at different stages as well as healthy and diseased controls. The utility of these 5 markers was evaluated for disease diagnosis and severity/progression correlation alone, as well as in combination with DJ‐1 and α‐synuclein. The major results were further validated in an independent cohort of cross‐sectional PD patients as well as in PD cases with CSF samples collected longitudinally. Results: The results demonstrated that combinations of these biomarkers could differentiate PD patients not only from normal controls but also from patients with Alzheimer disease (AD) and multiple system atrophy. Particularly, with CSF Flt3 ligand, PD could be clearly differentiated from multiple system atrophy, a disease that overlaps with PD clinically, with excellent sensitivity (99%) and specificity (95%). In addition, we identified CSF fractalkine/Aβ 1–42 that positively correlated with PD severity in cross‐sectional samples as well as with PD progression in longitudinal samples. Interpretation: We have demonstrated that this panel of 7 CSF proteins could aid in Parkinson disease diagnosis, differential diagnosis, and correlation with disease severity and progression. ANN NEUROL 2010
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationMicroglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism
Block, M. L., & Hong, J.-S. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.06.004 · Cited by 1,557
Control of microglial neurotoxicity by the fractalkine receptor
Cardona, A. E., Pioro, E. P., Sasse, M. E., Kostenko, V., Cardona, S. M., Dijkstra, I. M., Huang, D., Kidd, G., Dombrowski, S., Dutta, R., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1715 · Cited by 1,531 · cited 1×
“’’(48,51) Indeed, fractalkine was also reported to be important for neuroprotection, because Cx3cl (fractalkine) or Cx3cr1 deficient mice demonstrated enhanced neurotoxicity.(52) If this protective role of fractalkine were true in humans, the increased CSF levels of fractalkine in advanced and faster-progressing PD pa…”
BackgroundEffects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
Harrison, J. K., Jiang, Y., Chen, S., Xia, Y., Maciejewski, D., McNamara, R. K., Streit, W. J., Salafranca, M. N., Adhikari, S., Thompson, D. A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10896 · Cited by 1,176
Neuronal ‘On’ and ‘Off’ signals control microglia
Biber, K., Neumann, H., Inoue, K., & Boddeke, H. W. G. M. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.08.007 · Cited by 787
Thomas, B., & Beal, M. F. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm159 · Cited by 748
Association of olfactory dysfunction with risk for future Parkinson's disease
Ross, G. W., Petrovitch, H., Abbott, R. D., Tanner, C. M., Popper, J., Masaki, K., Launer, L., & White, L. R. (2008) · Annals of Neurology · doi:10.1002/ana.21291 · Cited by 742
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615
Self-citationMicroglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease
Fuhrmann, M., Bittner, T., Jung, C. K. E., Burgold, S., Page, R. M., Mitteregger, G., Haass, C., LaFerla, F. M., Kretzschmar, H., & Herms, J. (2010) · Nature Neuroscience · doi:10.1038/nn.2511 · Cited by 562
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease
Hampel, H., Bürger, K., Teipel, S. J., Bokde, A. L. W., Zetterberg, H., & Blennow, K. (2008) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.08.006 · Cited by 532
High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease
Vaillancourt, D. E., Spraker, M. B., Prodoehl, J., Abraham, I., Corcos, D. M., Zhou, X. J., Comella, C. L., & Little, D. M. (2009) · Neurology · doi:10.1212/01.wnl.0000340982.01727.6e · Cited by 438
Sjögren, M., Vanderstichele, H., Ågren, H., Zachrisson, O., Edsbagge, M., Wikkelsø, C., Skoog, I., Wallin, A., Wahlund, L.-O., Marcusson, J., et al. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.10.1776 · Cited by 436
Tokuda, T., Salem, S. A., Allsop, D., Mizuno, T., Nakagawa, M., Qureshi, M. M., Locascio, J. J., Schlossmacher, M. G., & El-Agnaf, O. M. A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.08.024 · Cited by 425
Mollenhauer, B., Cullen, V., Kahn, I., Krastins, B., Outeiro, T. F., Pepivani, I., Ng, J., Schulz-Schaeffer, W., Kretzschmar, H. A., McLean, P. J., et al. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.06.004 · Cited by 382
Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis
Tang, C. C., Poston, K. L., Eckert, T., Feigin, A., Frucht, S., Gudesblatt, M., Dhawan, V., Lesser, M., Vonsattel, J.-P., Fahn, S., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70002-8 · Cited by 354
DATATOP: A Multicenter Controlled Clinical Trial in Early Parkinson's Disease: Parkinson Study Group
(1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520460028009 · Cited by 354
Neuropathological spectrum of synucleinopathies
Jellinger, K. A. (2003) · Movement Disorders · doi:10.1002/mds.10557 · Cited by 340
Dénes, Á., Ferenczi, S., Halász, J., Környei, Z., & Kovács, K. J. (2008) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2008.64 · Cited by 276
CSF Multianalyte Profile Distinguishes Alzheimer and Parkinson Diseases
Zhang, J., Sokal, I., Peskind, E. R., Quinn, J. F., Jankovic, J., Kenney, C., Chung, K. A., Millard, S. P., Nutt, J. G., & Montine, T. J. (2008) · American Journal of Clinical Pathology · doi:10.1309/w01y0b808emeh12l · Cited by 264
Self-citationBoth total and phosphorylated tau are increased in Alzheimer's disease
Sjogren, M. (2001) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.5.624 · Cited by 253
Sjögren, M., Minthon, L., Davidsson, P., Granérus, A. K., Clarberg, A., Vanderstichele, H., Vanmechelen, E., Wallin, A., & Blennow, K. (2000) · Journal of Neural Transmission · doi:10.1007/s007020070079 · Cited by 239
Alves, G., Bronnick, K., Aarsland, D., Blennow, K., Zetterberg, H., Ballard, C., Kurz, M. W., Andreasson, U., Tysnes, O.-B., Larsen, J. P., et al. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.199950 · Cited by 221
Mandal, P. K., Pettegrew, J. W., Masliah, E., Hamilton, R. L., & Mandal, R. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9140-9 · Cited by 219
Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss?
Öhrfelt, A., Grognet, P., Andreasen, N., Wallin, A., Vanmechelen, E., Blennow, K., & Zetterberg, H. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2008.11.015 · Cited by 198
Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson’s disease
Waragai, M., Wei, J., Fujita, M., Nakai, M., Ho, G. J., Masliah, E., Akatsu, H., Yamada, T., & Hashimoto, M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.05.011 · Cited by 194
Compta, Y., Martí, M. J., Ibarretxe‐Bilbao, N., Junqué, C., Valldeoriola, F., Muñoz, E., Ezquerra, M., Ríos, J., & Tolosa, E. (2009) · Movement Disorders · doi:10.1002/mds.22594 · Cited by 185
CSF Aβ42 and tau in Parkinson's disease with cognitive impairment
Montine, T. J., Shi, M., Quinn, J. F., Peskind, E. R., Craft, S., Ginghina, C., Chung, K. A., Kim, H., Galasko, D. R., Jankovic, J., et al. (2010) · Movement Disorders · doi:10.1002/mds.23287 · Cited by 182
Self-citationCerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies
Parnetti, L., Tiraboschi, P., Lanari, A., Peducci, M., Padiglioni, C., D'Amore, C., Pierguidi, L., Tambasco, N., Rossi, A., & Calabresi, P. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.02.016 · Cited by 173
Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies
Kanemaru, K., Kameda, N., & Yamanouchi, H. (2000) · Neurology · doi:10.1212/wnl.54.9.1875 · Cited by 170
Biasini, E., Fioriti, L., Ceglia, I., Invernizzi, R., Bertoli, A., Chiesa, R., & Forloni, G. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02152.x · Cited by 167
Mollenhauer, B., Trenkwalder, C., von Ahsen, N., Bibl, M., Steinacker, P., Brechlin, P., Schindehütte, J., Poser, S., Wiltfang, J., & Otto, M. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000094871 · Cited by 145
Regional brain volumes distinguish PSP, MSA‐P, and PD: MRI‐based clinico‐radiological correlations
Paviour, D. C., Price, S. L., Jahanshahi, M., Lees, A. J., & Fox, N. C. (2006) · Movement Disorders · doi:10.1002/mds.20877 · Cited by 136
The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I
Litvan, I., Halliday, G. M., Hallett, M., Goetz, C. G., Rocca, W. A., Duyckaerts, C. J., Ben‐Shlomo, Y., Dickson, D. W., Lang, A. E., Chesselet, M., et al. (2007) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3180415e42 · Cited by 130
CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease
Abdo, W. F., Bloem, B. R., van Geel, W. J. A., Esselink, R. A. J., & Verbeek, M. M. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.010 · Cited by 130
Kim, T., Lim, H. K., Lee, J. Y., Kim, D., Park, S., Lee, C., & Lee, C. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.03.019 · Cited by 121
Holmberg, B., Johnels, B., Blennow, K., & Rosengren, L. (2002) · Movement Disorders · doi:10.1002/mds.10321 · Cited by 116
Microglial Activation in Alzheimers Disease
Schlachetzki, J. C. M., & Hüll, M. (2009) · Current Alzheimer Research · doi:10.2174/156720509790147179 · Cited by 111
Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias
Bibl, M., Mollenhauer, B., Lewczuk, P., Esselmann, H., Wolf, S., Trenkwalder, C., Otto, M., Stiens, G., Rüther, E., Kornhuber, J., et al. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001967 · Cited by 101
Combined assessment of tau and neuronal thread protein in Alzheimer’s disease CSF
Kahle, P. J., Jakowec, M. W., Teipel, S. J., Hampel, H. J., Petzinger, G. M., Monte, D. A. D., Silverberg, G. D., Möller, H. ‐., Yesavage, J. A., Tinklenberg, J. R., et al. (2000) · Neurology · doi:10.1212/wnl.54.7.1498 · Cited by 101
Mini ReviewFLT3: Receptor and Ligand
Drexler, H. G., & Quentmeier, H. (2004) · Growth Factors · doi:10.1080/08977190410001700989 · Cited by 92
Combined assessment of tau and neuronal thread protein in Alzheimer’s disease CSF
Averback, P. (2000) · Neurology · doi:10.1212/wnl.55.7.1068 · Cited by 89
Biological fluid biomarkers in neurodegenerative parkinsonism
Eller, M., & Williams, D. R. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.135 · Cited by 75
Blood‐based neurochemical diagnosis of vascular dementia: a pilot study
Bibl, M., Esselmann, H., Mollenhauer, B., Weniger, G., Welge, V., Liess, M., Lewczuk, P., Otto, M., Schulz, J. B., Trenkwalder, C., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04763.x · Cited by 58
Chua, S. J., Bielecki, R., Wong, C. J., Yamanaka, N., Rogers, I. M., & Casper, R. F. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.12.045 · Cited by 47
Brazel, C. Y., Ducceschi, M. H., Pytowski, B., et al. (2001) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2001.1033 · Cited by 40
Mollenhauer, B., Bibl, M., Esselmann, H., Steinacker, P., Trenkwalder, C., Wiltfang, J., & Otto, M. (2007) · Journal of Neural Transmission · doi:10.1007/s00702-007-0629-4 · Cited by 37
Fractalkine and TGF-β1 levels reflect the severity of chronic pancreatitis in humans
Yasuda, M., Ito, T., Oono, T., Kawabe, K., Kaku, T., Igarashi, H., Nakamura, T., & Takayanagi, R. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.6488 · Cited by 37
Biomarkers in Huntington's and Parkinson's Disease
O’Keeffe, G. C., Michell, A. W., & Barker, R. A. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04943.x · Cited by 32
Sniffing out Parkinson Disease: Can Olfactory Testing Differentiate Parkinsonian Disorders?
McKinnon, J. H., Demaerschalk, B. M., Caviness, J. N., Wellik, K. E., Adler, C. H., & Wingerchuk, D. M. (2007) · The Neurologist · doi:10.1097/nrl.0b013e31815a351a · Cited by 31
Tau protein concentrations in cerebrospinal fluid of non-demented Parkinson's disease patients
Molina, J. A., Benito‐León, J., Jiménez‐Jiménez, F. J., Pareja, M. O., Berbel, Á., Tallón-Barranco, A., Bustos, F., & Hernánz, Á. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00858-6 · Cited by 25
Cited by
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies
Irwin, D. J., Lee, V. M.-Y., & Trojanowski, J. Q. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3549 · Cited by 869
Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease
Shi, M., Liu, C., Cook, T. J., Bullock, K. M., Zhao, Y., Ginghina, C., Li, Y., Aro, P., Dator, R., He, C., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1314-y · Cited by 676
“4), which is the best molecular biomarker of PD described to date [27, 31, 50, 51, 58, 67].”
InfluentialSelf-citationAlpha‐synuclein RT ‐Qu IC in the CSF of patients with alpha‐synucleinopathies
Fairfoul, G., McGuire, L. I., Pal, S., Ironside, J. W., Neumann, J., Christie, S., Joachim, C., Esiri, M., Evetts, S. G., Rolinski, M., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.338 · Cited by 608
Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease
Gui, Y., Liu, H., Zhang, L., Lv, W., & Hu, X. (2015) · Oncotarget · doi:10.18632/oncotarget.6158 · Cited by 552
Metadata
- Authors
- Shi, M., Bradner, J., Hancock, A. M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Kim, H. M., Leverenz, J. B., Montine, T. J., Ginghina, C., Kang, U. J., Cain, K. C., Wang, Y., Aasly, J., Goldstein, D., & Zhang, J.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2011-03
- Volume
- 69
- Issue
- 3
- Pages
- 570-580
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2029085167
- Cited by
- 418
- References
- 51
- FWCI
- 17.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.